Sodium–Glucose Co-Transporter-2 Inhibitors and Cardiovascular Effects in Kidney Transplant Recipients With Diabetes Mellitus
Main finding · Acute coronary syndrome, stroke/transient ischemic attack, or deathResult — go to the resultAdjusted hazard ratio 0.64 95% CI 0.42–0.97Authors' conclusion
SGLT2i use was associated with lower rates of major cardiovascular events in KTRs with diabetes, without a significant reduction in hHF. Given the elevated cardiovascular risk in KTRs, these findings support further investigation of SGLT2i therapy in this population.
Study context
- Population
- Kidney transplant recipients with diabetes at a large transplant center; 20% women, median age 63–64 years; SGLT2i started 5.9 years (IQR 2.0–13.9) after transplantmatched cohort
- Participants
- 480 recipients
- Exposure
- SGLT2i vs other antihyperglycemic agents
- SGLT2in = 240
- Controln = 240reference
- Outcome
- Composite of:
- Acute coronary syndrome
- Stroke/transient ischemic attack
- All-cause mortality
- Follow-up
- Up to 3 years
Methodological detailsmatched cohort, single-centre
- Matched cohort
- Single-centre
Main finding
As reported in the abstract
Acute coronary syndrome, stroke/transient ischemic attack, or death
Adjusted hazard ratio
0.64
95% CI 0.42–0.97
P = 0.039
By group
SGLT2i
7.9 events per 100 person-years
Control
13.6 events per 100 person-years
SGLT2ivs Control
aHR 0.64 (95% CI 0.42–0.97); P = 0.039
Observational data: associations, not effects.
Further findings
Events per 100 person-years
| Outcome | SGLT2i | Control | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| HF hospitalization or all-cause mortalityAfter adjustment | 5.7 | 11.6 | 0.82 (0.50–1.32) | P = 0.410 | |
| 0.512Hazard ratio (log scale) |
Original publication
Sodium–Glucose Co-Transporter-2 Inhibitors and Cardiovascular Effects in Kidney Transplant Recipients With Diabetes Mellitus. Endocr Pract. Published 23 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →